Searched for
BRAZIL DIABETES MARKET
Dr Reddy's Laboratories receives ANVISA approval for generic semaglutide injection in BrazilDr Reddy’s Laboratories obtained marketing authorisation from Brazil’s ANVISA for a generic semaglutide injection. The product will be avai...- Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brok...
- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- ‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEOEli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...
- Sandoz bets big on biosimilars, aims to double group sales by 2035Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfoli...
- Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTDAurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The i...
- Widening waistline: India's big, fat obesity hotspots may not be just the biggest cities anymoreIndia sees a significant rise in overweight and obese populations recently. Rural areas show a particularly sharp increase in these health ...
- MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...
- Indian drugmakers flood market with cheaper versions of Novo's Ozempic, WegovyIndian drugmakers have launched affordable generic versions of popular diabetes and weight-loss drugs. This move significantly reduces trea...
- Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatmentEli Lilly's diabetes drug Mounjaro will be added to China's state health insurance from January 1, making it more accessible to the country...
- Biocon partners Biomm to commercialise diabetes drug in BrazilBiocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...
- Volume with low cost is Biocon Biologics’ big planThe Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors. The company plans to create an ecosyst...
- Abbott jumps on to digital health service bandwagonAbbott will also look at partnering with e-pharmacies, diagnostic chains and physicians to provide patients with discounts.
- US pharma firm Eli Lilly plans to launch new medication for diabetes in IndiaUS pharma major Eli Lilly plans to launch a new medication by the end of this year to enhance its diabetes treatment portfolio in India.
- India must follow Brazil's example in battling ultra-processed foodThe Delhi high court wrestled with defining `junk food', following the PIL by the Delhi-based Uday Foundation to ban such food in schools.
- Novo Nordisk launches diabetes drug Ryzodeg in IndiaNovo Nordisk launched it's combination diabetic drug Ryzodeg, priced at Rs 1,595 for 300 units, for people with type II diabetes in India.
- India will be potential market for wound care: ReportThe report said factors that would contribute to the growth of wound care market include rising awareness regarding new and advanced produc...
- Zydus to invest Rs 100 crore in Vadodara unit, expand hospital businessZydus Hospitals & Healthcare Research recently started its first hospital operations at Anand, better known as Amul's hometown.
- Lupin to replicate Japan model for expansion in various marketsLupin recently enhanced its presence in Japan with the acquisition of I'rom Pharmaceuticals in November this year for an undisclosed amount.
- Zydus files IND application with DCGI for diabetes and obesityHealthcare major, Zydus Cadila has filed IND (Investigational New Drug) application for anti-diabetic and anti-obesity drug with Drugs Cont...
Load More
